---
title: "Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292111129.md"
description: "On July 8, 2026, Candel Therapeutics, Inc. revealed that the Compensation Committee of its Board of Directors awarded Mark Sims, the new Chief Commercial Officer, stock options to buy 285,000 shares of common stock at an exercise price of $10.03 per share. The grant matches the closing price of Candel's common stock on The Nasdaq Global Market on July 6, 2026. Candel is a Nasdaq-listed clinical-stage biopharmaceutical firm with a focus on developing multimodal immunotherapies for enhancing cancer patient outcomes."
datetime: "2026-07-08T20:06:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292111129.md)
  - [en](https://longbridge.com/en/news/292111129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292111129.md)
---

# Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

On July 8, 2026, Candel Therapeutics, Inc. revealed that the Compensation Committee of its Board of Directors awarded Mark Sims, the new Chief Commercial Officer, stock options to buy 285,000 shares of common stock at an exercise price of $10.03 per share. The grant matches the closing price of Candel's common stock on The Nasdaq Global Market on July 6, 2026. Candel is a Nasdaq-listed clinical-stage biopharmaceutical firm with a focus on developing multimodal immunotherapies for enhancing cancer patient outcomes.

### Related Stocks

- [CADL.US](https://longbridge.com/en/quote/CADL.US.md)

## Related News & Research

- [Candel Therapeutics Insider Ups Holding By 14% During Year](https://longbridge.com/en/news/293099365.md)
- [Scorpio Gold pursues Nasdaq listing for American depositary shares](https://longbridge.com/en/news/293905134.md)
- [Scorpio Gold Moves to Launch Nasdaq ADS Listing to Expand U.S. Investor Reach](https://longbridge.com/en/news/293950190.md)
- [Incyte beats Q2 revenue estimates on strong product demand](https://longbridge.com/en/news/294056660.md)
- [Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer program](https://longbridge.com/en/news/293929420.md)